Brind.
  1. Incannex Healthcare Inc. is developing IHL-42X for Obstructive Sleep Apnoea (OSA) treatment, showing significant efficacy.

Kirsch joins the advisory board to support the advancement of IHL-42X for Obstructive Sleep Apnoea (OSA) treatment.

1 report, 0 independent Updated Jun 24
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

SpeculativeNo independent reporting found

Kirsch joins the advisory board to support the advancement of IHL-42X for Obstructive Sleep Apnoea (OSA) treatment.

Who's involved

What this event is mainly about
Kirsch

Keep exploring

Part of

Incannex Healthcare Inc. is developing IHL-42X for Obstructive Sleep Apnoea (OSA) treatment, showing significant efficacy. All 1 developments

The entities involved

Coverage

Newest first; wire copies grouped
  • Unknown outlet